Noxopharm Annual Report 2022

Annual Report 2022 43 Note 17. Key management personnel disclosures Other key management personnel The following persons also had the authority and responsibility for planning, directing and controlling the major activities of the consolidated entity, directly or indirectly, during the financial year: • Mr. Frederic Bart - Non Executive Chairman • Dr. Graham Kelly - Non Executive Director (resigned executive positions and appointed Non Executive Director 1 February 2022) • Mr. Peter Marks - Non Executive Director and Deputy Chairman • Mr. Boris Patkin - Non Executive Director • Dr. Gisela Mautner - Chief Executive Officer and Managing Director (appointed 1 February 2022) Compensation The aggregate compensation made to directors and other members of key management personnel of the consolidated entity is set out below: Consolidated 2022 2021 $ $ Short-term employee benefits 718,093 479,495 Post-employment benefits 47,701 34,881 Long-term benefits 5,350 341 Share-based payments 679,743 1,418,819 1,450,887 1,933,536 Note 18. Remuneration of auditors During the financial year the following fees were paid or payable for services provided by William Buck Audit (Vic) Pty Ltd, the auditor of the company: Consolidated 2022 2021 $ $ Audit services - William Buck Audit (Vic) Pty Ltd Audit or review of the financial statements 59,500 66,450

RkJQdWJsaXNoZXIy MjE2NDg3